Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH001 in Allergic Asthma
NCT07070297Phase 1Completed
- Sponsor
- Kanova
- Start
- Dec 2023
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XKH001 Placebo Injection in allergic asthma, sponsored by Kanova. Primary endpoints: Effect on Airway Hyperresponsiveness at Day 169 and Safety and Tolerability at Day 169. Started Dec 2023; status: completed.
02
Drugs
XKH001 Placebo Injection
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT07070297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070297.